Bal Pharma Ltd

Bal Pharma Ltd Share Price Today: Live Updates & Key Insights

Get insights on Bal Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Bal Pharma Ltd Share Price Chart

Bal Pharma Ltd Fundamentals

Traded Volume: 4,585

Market Cap(Cr): 122

Avg Traded Price 76.68

1 Year return -43.07%

Upper Circuit 77.8

Lower Circuit 75.5

P/E TTM 18.00

P/B Ratio 4.00

Traded Value(Cr) 3.51

EPS TTM 4.287

Book value 4.287

Dividend 2.00%

Bal Pharma Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Bal Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Bal Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -4.17%

1M -5.42%

3M -13.89%

1Y -43.07%

YTD -38.20%

Bal Pharma Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Bal Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 7556.00

Day Before Yesterday 12015.00

1W Avg 6779.80

1M Avg 10111.95

3M Avg 21303.37

Bal Pharma Ltd Technical Details

Bal Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 75

Support 2 74

Support 3 73

Pivot Point : 77

Resistance 1 78

Resistance 2 79

Resistance 3 80

Bal Pharma Ltd Corporate Actions

Bal Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Bal Pharma Ltd’s capital allocation strategies.

All

Ex-Date 18-Sep-2025 Type D Description 1.20/share@12.00% Record Date 18-Sep-2025 Ratio 12.00

Ex-Date 17-Sep-2024 Type D Description 1.20/share@12.00% Record Date - Ratio 12.00

Ex-Date 18-Sep-2023 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 13-Sep-2022 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 16-Sep-2021 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 17-Sep-2019 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 14-Sep-2018 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 14-Sep-2017 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 15-Sep-2016 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 15-Sep-2015 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 12-Sep-2014 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 12-Sep-2013 Type D Description 0.75/share@7.50% Record Date - Ratio 7.50

Ex-Date 17-Sep-2009 Type D Description 0.75/share@7.50% Record Date - Ratio 7.50

Ex-Date 09-Sep-2008 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Ex-Date 07-Sep-2007 Type D Description 0.75/share@7.50% Record Date - Ratio 7.50

Dividends

Announcement Date 18-Sep-2025 Ex Dividend Date 18-Sep-2025 Dividend(%) 12

Announcement Date 17-Sep-2024 Ex Dividend Date 17-Sep-2024 Dividend(%) 12

Announcement Date 18-Sep-2023 Ex Dividend Date 18-Sep-2023 Dividend(%) 10

Announcement Date 13-Sep-2022 Ex Dividend Date 13-Sep-2022 Dividend(%) 10

Announcement Date 16-Sep-2021 Ex Dividend Date 16-Sep-2021 Dividend(%) 10

Announcement Date 17-Sep-2019 Ex Dividend Date 17-Sep-2019 Dividend(%) 10

Announcement Date 14-Sep-2018 Ex Dividend Date 14-Sep-2018 Dividend(%) 10

Announcement Date 14-Sep-2017 Ex Dividend Date 14-Sep-2017 Dividend(%) 10

Announcement Date 15-Sep-2016 Ex Dividend Date 15-Sep-2016 Dividend(%) 10

Announcement Date 15-Sep-2015 Ex Dividend Date 15-Sep-2015 Dividend(%) 10

Announcement Date 12-Sep-2014 Ex Dividend Date 12-Sep-2014 Dividend(%) 10

Announcement Date 12-Sep-2013 Ex Dividend Date 12-Sep-2013 Dividend(%) 8

Announcement Date 17-Sep-2009 Ex Dividend Date 17-Sep-2009 Dividend(%) 8

Announcement Date 09-Sep-2008 Ex Dividend Date 09-Sep-2008 Dividend(%) 10

Announcement Date 07-Sep-2007 Ex Dividend Date 07-Sep-2007 Dividend(%) 8

Bonus

No Bonus has been declared by BALPHARMA

Splits

No Split has been declared by BALPHARMA

Others

Rights No Rights has been declared by BALPHARMA

Bal Pharma Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Bal Pharma Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Bal Pharma Ltd's relative performance and valuation against major competitors.

Stock Name Sotac Pharmaceuticals Ltd ₹125.00 (0.00%) M. Cap (Cr) 1.38 1 Yr Return (%) +4.87% P/E (TTM) 17.21 PB Ratio 2.93

Stock Name Vaishali Pharma Ltd ₹9.47 (-2.27%) M. Cap (Cr) 1.02 1 Yr Return (%) -43.05% P/E (TTM) -320.04 PB Ratio 1.82

Stock Name Tyche Industries Ltd ₹120.00 (-0.83%) M. Cap (Cr) 1.23 1 Yr Return (%) -36.59% P/E (TTM) 12.73 PB Ratio 0.91

Stock Name Bal Pharma Ltd ₹76.57 (-1.51%) M. Cap (Cr) 1.22 1 Yr Return (%) -43.07% P/E (TTM) 17.86 PB Ratio 1.57

Stock Name Denis Chem Lab Ltd ₹85.00 (-2.98%) M. Cap (Cr) 1.18 1 Yr Return (%) -46.22% P/E (TTM) 16.71 PB Ratio 1.41

Stock Name Par Drugs & Chemicals Ltd ₹92.23 (-0.45%) M. Cap (Cr) 1.13 1 Yr Return (%) -67.22% P/E (TTM) 11.72 PB Ratio 1.17

Stock Name Curis Lifesciences Ltd ₹137.50 (+2.57%) M. Cap (Cr) 1.11 1 Yr Return (%) NaN% P/E (TTM) 18.21 PB Ratio 5.23

Bal Pharma Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Bal Pharma Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 20.31 Mar 2024 28.95 Mar 2023 5.07 Mar 2022 31.48 Mar 2021 10.24

PARTICULARS Investing Activities Mar 2025 -14.90 Mar 2024 -18.43 Mar 2023 -22.08 Mar 2022 -13.43 Mar 2021 -6.66

PARTICULARS Financing Activities Mar 2025 -7.83 Mar 2024 -7.71 Mar 2023 17.43 Mar 2022 -18.13 Mar 2021 -3.36

PARTICULARS Net Cash Flow Mar 2025 -2.42 Mar 2024 2.81 Mar 2023 0.42 Mar 2022 -0.08 Mar 2021 0.21

Bal Pharma Ltd Shareholding Pattern

This shows the ownership breakdown of Bal Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 50.86%

Public 48.91%

Other Institutions 0.0%

FII 0.23%

Mutual Funds null%

About Bal Pharma Ltd

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May `87. In Mar.`90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.`95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company`s product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named "SERVETUS" has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug`s manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.

ED / MD / Promoter

Shailesh Siroya

Registered office 21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092

FAX :null

Background

Incorporation Year 1987

Face Value ₹10.00

Market Lot 1

Bal Pharma Ltd Latest News

VIEW MORE NEWS

FAQs on Bal Pharma Ltd